On Oct. 29, Pfizer (PFE) announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on an operational basis, driven by higher sales of key non-COVID products like Vyndaqel and Eliquis, new product launches and newly acquired products from Seagen.Sales of COVID products were higher than expected, driving most of the outperformance. Drugs added from last year’s Seagen acquisition contributed $854 million to the top line in the third quarter. Revenues from Pfizer’s non- ...